Zürcher Nachrichten - EU eyes autumn approval of Pfizer jab for Covid variants

EUR -
AED 3.821609
AFN 73.043711
ALL 98.561994
AMD 415.734952
ANG 1.874008
AOA 948.892795
ARS 1067.239304
AUD 1.668181
AWG 1.872815
AZN 1.757682
BAM 1.956454
BBD 2.099482
BDT 124.256752
BGN 1.957817
BHD 0.392426
BIF 3074.798113
BMD 1.040453
BND 1.412959
BOB 7.185402
BRL 6.442694
BSD 1.039838
BTN 88.511732
BWP 14.441688
BYN 3.402905
BYR 20392.87375
BZD 2.092379
CAD 1.496535
CDF 2986.099191
CHF 0.93648
CLF 0.037319
CLP 1029.739995
CNY 7.591767
CNH 7.598484
COP 4556.381863
CRC 527.971385
CUC 1.040453
CUP 27.571998
CVE 110.297624
CZK 25.115501
DJF 185.171889
DKK 7.460816
DOP 63.34117
DZD 140.687327
EGP 52.961546
ERN 15.606791
ETB 132.39725
FJD 2.412966
FKP 0.82402
GBP 0.828196
GEL 2.923108
GGP 0.82402
GHS 15.285109
GIP 0.82402
GMD 74.912518
GNF 8986.65805
GTQ 8.0096
GYD 217.552711
HKD 8.081868
HNL 26.41983
HRK 7.46307
HTG 135.964135
HUF 410.690109
IDR 16866.571316
ILS 3.790359
IMP 0.82402
INR 88.614737
IQD 1362.155262
IRR 43790.051599
ISK 145.091415
JEP 0.82402
JMD 162.007918
JOD 0.737991
JPY 163.632522
KES 134.384575
KGS 90.519253
KHR 4179.356665
KMF 484.981066
KPW 936.406886
KRW 1516.386879
KWD 0.320615
KYD 0.866581
KZT 538.684863
LAK 22740.381777
LBP 93117.221839
LKR 306.450641
LRD 189.251433
LSL 19.334876
LTL 3.072187
LVL 0.629359
LYD 5.10451
MAD 10.485801
MDL 19.185228
MGA 4904.592084
MKD 61.579021
MMK 3379.349922
MNT 3535.458283
MOP 8.3185
MRU 41.508277
MUR 48.974372
MVR 16.027812
MWK 1803.102637
MXN 20.964801
MYR 4.668508
MZN 66.48881
NAD 19.335062
NGN 1610.226956
NIO 38.262788
NOK 11.815418
NPR 141.618971
NZD 1.843304
OMR 0.40057
PAB 1.039848
PEN 3.871945
PGK 4.220248
PHP 60.807174
PKR 289.478921
PLN 4.256856
PYG 8109.710445
QAR 3.781864
RON 4.974508
RSD 116.972699
RUB 104.513453
RWF 1450.570871
SAR 3.90625
SBD 8.722693
SCR 14.683216
SDG 625.834202
SEK 11.538871
SGD 1.414875
SHP 0.82402
SLE 23.721196
SLL 21817.776932
SOS 594.292914
SRD 36.476165
STD 21535.271101
SVC 9.098691
SYP 2614.168982
SZL 19.343279
THB 35.541837
TJS 11.375802
TMT 3.651989
TND 3.315608
TOP 2.436845
TRY 36.690385
TTD 7.066294
TWD 34.011368
TZS 2517.895925
UAH 43.598696
UGX 3806.235546
USD 1.040453
UYU 46.28369
UZS 13423.970506
VES 53.661818
VND 26469.117766
VUV 123.524633
WST 2.87455
XAF 656.17
XAG 0.035166
XAU 0.000398
XCD 2.811876
XDR 0.797259
XOF 656.151075
XPF 119.331742
YER 260.503326
ZAR 19.427453
ZMK 9365.323193
ZMW 28.777618
ZWL 335.025359
  • RBGPF

    -0.7000

    59.8

    -1.17%

  • RYCEF

    -0.0200

    7.25

    -0.28%

  • CMSC

    -0.2161

    23.686

    -0.91%

  • RIO

    -0.1100

    59.12

    -0.19%

  • SCS

    -0.0200

    11.63

    -0.17%

  • GSK

    -0.0250

    34.035

    -0.07%

  • RELX

    0.1300

    45.72

    +0.28%

  • NGG

    -0.3700

    58.65

    -0.63%

  • CMSD

    -0.2380

    23.312

    -1.02%

  • AZN

    -0.3300

    66.3

    -0.5%

  • VOD

    0.0810

    8.451

    +0.96%

  • BCC

    0.1700

    122.41

    +0.14%

  • BTI

    -0.0200

    36.2

    -0.06%

  • BCE

    0.1200

    22.96

    +0.52%

  • JRI

    0.0500

    12.15

    +0.41%

  • BP

    0.0800

    28.83

    +0.28%

EU eyes autumn approval of Pfizer jab for Covid variants
EU eyes autumn approval of Pfizer jab for Covid variants / Photo: SEBASTIEN BOZON - AFP/File

EU eyes autumn approval of Pfizer jab for Covid variants

The EU's medicines watchdog said Wednesday it aims to approve this autumn a Pfizer/BioNTech Covid vaccine adapted for two fast-spreading subvariants of the Omicron strain.

Text size:

Milder but more infectious than earlier types of the Covid virus, the BA.4 and BA.5 types have helped to drive a wave of new cases of the disease in Europe and the United States.

The European Medicines Agency (EMA) said it had launched a review on Monday of an adapted version of the Pfizer jab targeting those two types, which are more transmissible and immune evasive than earlier variants.

"EMA is expecting to receive an application for the BA.4/5 adapted vaccine developed by Pfizer/BioNTech, which will be evaluated for a potential rapid approval in the fall," an EMA spokesman told AFP in an emailed statement.

That would come "shortly after" the expected approval of two other adapted vaccines by Pfizer and its rival Moderna, which target both the original Covid virus and the earlier BA.1 subvariant of Omicron, the spokesman said.

Both Pfizer and Moderna had lodged separate applications for approval of those vaccines on July 22, the spokesman added.

The EMA, which oversees medicines for the 27-nation European Union, has previously said the first Omicron-adapted jabs could be approved as early as September.

- 'Nowhere near over' -

While vaccines have helped lower hospitalisations and deaths from Covid, which first emerged in China in late 2019, the current jabs are mainly aimed at the earlier strains of the disease.

The World Health Organization warned in July that the pandemic was "nowhere near over", due to the spread of Omicron subvariants and to the lifting of control measures.

Covid cases rose around the world in late spring and early summer, driven by the new variants, but have since started to plateau in Europe.

European nations are now starting to look ahead to the autumn and winter season, when cases are expected to peak once more.

The EU said on Tuesday it had agreed with Moderna to delay vaccine deliveries scheduled for the summer to wait for jabs that are adapted for new Omicron variants.

The WHO and the EU's health and medicine agencies have meanwhile all recently recommended a second booster shot for older people.

The BA.4 and BA.5 variants were first discovered in South Africa and spread rapidly despite high population immunity conferred by prior waves and vaccinations.

Like other Omicron variants, they tend to have a milder disease course as they settle less in the lungs and more in the upper nasal passages, causing symptoms like fever, tiredness and loss of smell.

O.Krasniqi--NZN